- Home
- VNDA
as 03-26-2025 2:37pm EST
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 282.8M | IPO Year: | 2006 |
| Target Price: | $16.50 | AVG Volume (30 days): | 584.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.86 - $6.75 | Next Earning Date: | 05-07-2025 |
| Revenue: | $198,772,000 | Revenue Growth: | 3.18% |
| Revenue Growth (this year): | 14.36% | Revenue Growth (next year): | 44.53% |
Stock Insider Trading Activity of Vanda Pharmaceuticals Inc. (VNDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 6 '25 | Buy | $5.02 | 10,000 | $50,150.00 | 2,295,731 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 5 '25 | Buy | $5.02 | 10,000 | $50,200.00 | 2,295,731 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 1 '25 | Buy | $4.71 | 10,000 | $47,050.00 | 2,295,731 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Feb 28 '25 | Buy | $4.76 | 10,000 | $47,600.00 | 2,295,731 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Feb 27 '25 | Buy | $4.76 | 10,000 | $47,600.00 | 2,295,731 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Feb 26 '25 | Buy | $4.77 | 10,000 | $47,650.00 | 2,295,731 | |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Feb 25 '25 | Buy | $4.46 | 10,000 | $44,640.00 | 2,295,731 | |
| Moran Kevin Patrick | VNDA | SVP, CFO & Treasurer | Feb 21 '25 | Buy | $4.39 | 2,000 | $8,778.80 | 355,763 |
Latest Vanda Pharmaceuticals Inc. News
VNDA Breaking Stock News: Dive into VNDA Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Daily – Vickers Top Insider Picks for 03/26/2025
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 03/25/2025
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 03/24/2025
Argus Research
6 days ago
Daily – Vickers Top Insider Picks for 03/21/2025
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 03/20/2025
Argus Research
8 days ago
Daily – Vickers Top Insider Picks for 03/19/2025
Argus Research
9 days ago
Daily – Vickers Top Insider Picks for 03/18/2025
MT Newswires
10 days ago
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate
Compare VNDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNDA Vanda Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.